Technical Analysis for MDNA - Medicenna Therapeutics Corp.

Grade Last Price % Change Price Change
B 1.640 -1.80% -0.030
MDNA closed down 1.8 percent on Friday, April 19, 2024, on 47 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
20 DMA Resistance Bearish -1.80%
Calm After Storm Range Contraction -1.80%
NR7 Range Contraction -1.80%
Wide Bands Range Expansion -1.80%
Down 3 Days in a Row Weakness -1.80%
Down 4 Days in a Row Weakness -1.80%

   Recent Intraday Alerts

Alert Time
Down 5% about 17 hours ago
Down 3% about 17 hours ago
Down 2% about 17 hours ago
Possible NR7 about 19 hours ago
Fell Below Previous Day's Low about 20 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Medicenna Therapeutics Corp. Description

Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinic Drug Cancer Medical Specialties Clinical Trial Oncology Clinical Medicine Cancers Tumor Immunotherapy Stem Cells Treatment Of Cancer Cancer Immunotherapy Tumors

Is MDNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.1
52 Week Low 0.215
Average Volume 173,945
200-Day Moving Average 0.696
50-Day Moving Average 1.396
20-Day Moving Average 1.751
10-Day Moving Average 1.781
Average True Range 0.187
RSI (14) 50.25
ADX 29.97
+DI 23.354
-DI 23.304
Chandelier Exit (Long, 3 ATRs) 1.538
Chandelier Exit (Short, 3 ATRs) 1.942
Upper Bollinger Bands 2.048
Lower Bollinger Band 1.454
Percent B (%b) 0.31
BandWidth 33.916
MACD Line 0.103
MACD Signal Line 0.145
MACD Histogram -0.0428
Fundamentals Value
Market Cap 80.36 Million
Num Shares 49 Million
EPS -0.19
Price-to-Earnings (P/E) Ratio -8.82
Price-to-Sales 0.00
Price-to-Book 7.03
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.850
Resistance 3 (R3) 1.853 1.787 1.815
Resistance 2 (R2) 1.787 1.733 1.785 1.803
Resistance 1 (R1) 1.713 1.700 1.680 1.710 1.792
Pivot Point 1.647 1.647 1.630 1.645 1.647
Support 1 (S1) 1.573 1.593 1.540 1.570 1.488
Support 2 (S2) 1.507 1.560 1.505 1.477
Support 3 (S3) 1.433 1.507 1.465
Support 4 (S4) 1.430